We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Judicial Panel on Multidistrict Litigation is consolidating price-fixing suits against generics makers Covis Pharmaceuticals’ heart drug Lanoxin in Pennsylvania federal court. Read More
Healthcare providers spent $121 billion on prescription drugs covered under the Medicare Part D program in 2014, representing a 12.6 rise in spending from 2013. Read More
A federal judge rendered Janssen’s composition patent for Remicade invalid, marking a loss for the company engaged in ongoing efforts to block biosimilar competition. Read More
The UK’s drug pricing watchdog has recommended that the National Health Service reimburse Pfizer lung cancer drug Xalkori, while rejecting to refund Novartis’ breast cancer therapy Everolimus and Janssen’s non-Hodgkin’s lymphoma drug Imbruvica. Read More
Investment firms T. Rowe and Alleghany have filed a suit against Valeant and six executives over the company’s sales strategy that involved price gouging and acquisitions, claiming those tactics cost investors billions. Read More
The UK’s drug pricing watchdog has recommended that the National Health Service reimburse Pfizer lung cancer drug Xalkori, while recommending against refunds for Novartis’ breast cancer therapy Everolimus and Janssen’s non-Hodgkin’s lymphoma drug Imbruvica. Read More
Less than a day after finalizing its acquisition of Allergan’s generics division, Israeli drugmaker Teva Pharmaceutical disclosed plans to pick up the company’s distribution arm for $500 million. Read More
Almost a year after Bayer settled pay-for-delay allegations involving its antibiotic Cipro, Allergan and Sanofi units have struck deals to resolve lingering Cipro claims in ongoing class action litigation, agreeing to pony up $100 million. Read More